Bingjing Intelligent Completes Nearly 100M Yuan Financing, with T-Capital as Financial Advisor: The Domestic Breakthrough of an Interventional Ultrasound Platform Company
Recently, the intelligent interventional ultrasound imaging platform company Bingjing Intelligent announced the completion of two consecutive rounds of financing, with a total amount of nearly 100 million yuan. Institutions participating in the relevant financing include Bank of China International, Jiangxia Science and Technology Investment, and Shengke Zhizao. The financing will be mainly used for the construction of production bases, operations, and supplementary working capital.
T-Capital served as the main financial advisor for the relevant financing rounds, assisting Bingjing Intelligent in completing this round of financing.
Founded in 2021, Bingjing Intelligent focuses on clinical application scenarios such as structural heart disease and electrophysiology, and has established an interventional ultrasound imaging technology platform centered on Intracardiac Echocardiography (ICE). The company’s core team comes from leading healthcare industry companies such as GE, Johnson & Johnson, Siemens, Abbott, and Kaili, with team capabilities covering intracardiac intervention, medical imaging, medical devices, consumables, and artificial intelligence.
Unlike single-product companies, Bingjing Intelligent positions itself as an intelligent interventional ultrasound technology platform company, with cardiac interventional ultrasound as its core, and continues to expand into application directions such as digestive tract interventional ultrasound, tracheal interventional ultrasound, coronary interventional ultrasound, and peripheral interventional ultrasound.
I. From a Single Product to an Interventional Ultrasound Technology Platform
Intracardiac Echocardiography (ICE) is an important imaging tool in interventional cardiac surgery.
Unlike traditional transthoracic echocardiography, ICE uses a catheter to enter the heart to obtain real-time ultrasound images, providing doctors with intraoperative anatomical structures and operational information. It has important application value in interventional surgeries such as structural heart disease and electrophysiology.
Bingjing Intelligent’s product layout is not limited to a single ICE product.
The company conducts research and development around the interventional ultrasound imaging chain, covering:
- Transducers;
- Ultrasound probes;
- Ultrasound mainframes;
- Image processing;
- AI algorithms;
- Interventional ultrasound-related software and systems.
Public information shows that Bingjing Intelligent is currently focusing on cardiac interventional ultrasound and continues to promote product and technology roadmaps such as 2D, HD, 3D, and 4D ICE.
This platform-based approach allows the company’s competitive logic to gradually extend from a single product to synergistic research and development of core components, imaging systems, algorithms, and clinical application scenarios.
II. Full-Chain Independent R&D is an Important Foundation for Bingjing Intelligent’s Domestication Path
The domestication of high-end medical imaging equipment is not just about completing the assembly of the entire machine.
For interventional ultrasound equipment, from transducers, probes, and mainframes to image processing and algorithms, multiple technical links are required to form a complete product system.
One of the important features of Bingjing Intelligent is the establishment of independent research and development capabilities around the interventional ultrasound imaging chain.
According to public information, the company has achieved independent research and development in links from transducers, probes, and mainframes to image processing and AI algorithms, and continues to promote the domestication of core components and supply chains.
For high-end medical device companies, this capability has multiple meanings.
First, reduce reliance on external supply chains for core components
Independent research and development of core components can help companies improve supply chain controllability and provide greater engineering space for product iteration.
Second, promote synergistic optimization of software and hardware
There is a strong correlation between the hardware, signal processing, image algorithms, and AI capabilities of ultrasound equipment.
If the core links are continuously optimized by the same R&D system, product iteration can be carried out more quickly around clinical needs.
Third, provide a technical foundation for the research and development of next-generation products
Platform-based technical capabilities can support the company’s further expansion from 2D ICE to HD, 3D, 4D ICE, and AI-assisted applications.
Therefore, Bingjing Intelligent’s domestication path is not only a cost logic of “domestic substitution,” but also includes the autonomy of the technology platform and the construction of product iteration capabilities.
III. Commercialization Enters a New Stage After the First Product is Approved
Bingjing Intelligent’s 2D ICE product was approved for marketing in February 2025 and participated in centralized procurement in relevant regions in 2025.
Public reports show that the product has been used in clinical applications in medical institutions such as Beijing Anzhen Hospital, Fuwai Hospital, and Shanghai Zhongshan Hospital, and has undergone human clinical trials.
In the centralized procurement in Sichuan, Bingjing Intelligent’s relevant domestic products have achieved a certain market coverage.
For medical device companies, moving from the R&D stage to the commercialization stage usually means that the company’s core capabilities begin to change.
The company needs to face at the same time:
- Product registration;
- Mass production;
- Supply chain management;
- Hospital access;
- Centralized procurement;
- Clinical promotion;
- After-sales service;
- Commercialization team building.
Therefore, obtaining a registration certificate is only the starting point of medical device commercialization, not the end point.
Bingjing Intelligent’s continued promotion of production and commercialization capacity building after obtaining product registration is also one of the important backgrounds of this round of financing.
IV. Extending from 2D ICE to 4D ICE
While promoting the commercialization of basic products, Bingjing Intelligent is also continuously developing next-generation interventional ultrasound products.
Among them, 4D ICE is one of the key technological directions that the company is focusing on.
Public information shows that Bingjing Intelligent has completed the sample production of an 896-element commercial-grade electronic matrix transducer and is conducting related research and development around 4D ICE.
Compared with traditional 2D imaging, 3D/4D technology can provide richer spatial information.
For cardiac interventional surgery with complex structures and obvious real-time changes, richer three-dimensional imaging information has the potential to further support doctors’ judgment of complex anatomical structures.
However, from R&D samples to final commercialization, it still needs to go through multiple stages such as product development, clinical verification, registration approval, and mass production.
Therefore, 4D ICE is also an important direction for Bingjing Intelligent’s subsequent technology and product system construction, rather than a mature product that has been commercialized.
V. Why is Interventional Ultrasound Becoming an Important Track for the Domestication of Medical Devices?
In recent years, with the development of structural heart disease and electrophysiological interventional therapy, the demand for intraoperative imaging has continued to receive attention.
Especially in the field of electrophysiology, intracardiac ultrasound can help doctors obtain real-time intracardiac images and provide imaging support for complex interventional operations.
At the same time, domestic medical device companies are constantly entering the field of high-end imaging equipment that was previously dominated by international manufacturers.
From an industry perspective, there are several important factors behind this trend.
1. Continuous increase in clinical demand
With the development of cardiac interventional surgery technology, the demand for real-time, high-quality, and operable intraoperative imaging tools continues to increase.
2. Improvement of R&D capabilities of domestic medical device companies
More and more domestic enterprises are beginning to enter the core technology field of high-end medical devices, gradually extending from simple product manufacturing to the research and development of core components, software, algorithms, and systems.
3. Gradual maturity of the domestic supply chain
The improvement of the domestication capabilities of core components, electronic components, software, and algorithms has provided a new industrial foundation for high-end medical device companies.
4. Changes in the commercialization environment for medical devices
Factors such as registration, centralized procurement, hospital access, and clinical application are jointly affecting the product commercialization path of medical device companies.
Therefore, the competition in interventional ultrasound is no longer just a competition between individual products, but also gradually reflects a comprehensive competition between:
Technology platform + Core components + Product system + Clinical capabilities + Commercialization capabilities
VI. What Does Financing Mean for Bingjing Intelligent?
This round of financing will be mainly used for:
- Construction of production bases;
- Production and operation;
- Supplementary working capital;
- Subsequent product and business development.
For medical device companies that have entered the product commercialization stage, the use of financing funds is significantly different from that in the early R&D stage.
Early-stage financing usually focuses on supporting:
R&D → Prototype → Animal experiments → Clinical trials
After entering the commercialization stage, the company needs to further solve:
Registration → Mass production → Hospital access → Commercialization → Product iteration
Therefore, for Bingjing Intelligent, this round of financing is not only support at the capital level, but also means that the company is further advancing from the technology R&D stage to the large-scale industrialization stage.
VII. T-Capital Serves as Financial Advisor to Help Medical Device Companies with Financing
In this round of financing, T-Capital served as the main financial advisor, assisting Bingjing Intelligent in completing the financing.
The financing of medical device companies is significantly different from that of general technology companies.
In addition to paying attention to the company’s revenue and market space, investors also need to understand:
- Medical device registration pathway;
- Clinical data;
- Product competitive landscape;
- Core technology;
- Supply chain;
- Hospital access;
- Impact of centralized procurement;
- Commercialization progress;
- Next-generation product pipeline.
Therefore, the financing of medical device companies needs to simultaneously establish the connection between technical value, clinical value, commercial value, and capital value.
For medical device companies with core technologies and product pipelines, the role of professional capital advisors is not only to connect with investment institutions, but also to help companies sort out:
Company positioning → Technology barriers → Product pipeline → Commercialization progress → Market opportunities → Financing logic
and transform these elements into a capital market narrative that investors can understand and evaluate.
VIII. From “Domestic Substitution” to “Independent Innovation”
Bingjing Intelligent’s development path also reflects a change that is taking place in China’s high-end medical device industry.
Early domestic substitution emphasized more on:
Being able to produce similar products.
As the technical capabilities of domestic medical device companies improve, the focus of competition is gradually shifting to:
Whether they can establish their own core technology platforms and continuously launch next-generation products.
This change is particularly evident for technology-intensive products such as interventional ultrasound.
From transducers to imaging systems, from 2D to 4D, and then to AI-assisted applications, companies need to continue to invest in research and development.
Therefore, truly long-term competitive domestication is not just about reducing product prices, but about establishing a complete industrial chain capability consisting of:
Autonomy of core technology + Autonomy of supply chain + Product innovation + Clinical verification + Commercialization capability
IX. Bingjing Intelligent: From an Interventional Ultrasound Product to an Intelligent Platform
Bingjing Intelligent currently focuses on cardiac interventional ultrasound and continues to expand to a wider range of interventional ultrasound scenarios.
The company’s official website shows that its long-term goal is to develop new ICE technologies and intelligent solutions around the clinical needs in cardiac interventional therapy.
From the perspective of the product development path, the company is going through three stages:
First Stage: Core Technology R&D
Establish a core technology and product R&D system for interventional ultrasound.
Second Stage: Product Registration and Commercialization
Promote the registration and market entry of products such as 2D ICE.
Third Stage: Platformization and Intelligence
Further lay out HD, 3D, 4D, and AI-related technologies and products.
This means that the company’s long-term value does not entirely depend on a single product, but on whether it can continuously transform its technical capabilities into new products and clinical applications.
X. T-Capital Focuses on the Long-Term Capital Value of Medical Device Companies
As a boutique investment bank focusing on the healthcare field, T-Capital has long been paying attention to subdivided fields of healthcare such as medical devices, innovative drugs, medical diagnostics, life sciences, and emerging technologies.
In the field of medical devices, it usually takes a long time for companies to go from technology R&D to commercialization, and they also need continuous capital support.
Therefore, the financing transaction itself is not the end point of the company’s development.
For medical device companies, what is more important is to obtain through the capital market:
- R&D resources;
- Industrial resources;
- Commercialization resources;
- Strategic partners;
- Long-term capital support.
T-Capital hopes to help healthcare companies connect capital and industrial resources through professional financing advisory and capital transaction services, and promote the further realization of technology, product, and commercial value.
About Bingjing Intelligent
Founded in 2021, Bingjing Intelligent focuses on the research and development of interventional ultrasound imaging technology and products in fields such as structural heart disease and electrophysiology. It has established a technology platform centered on intracardiac ultrasound and continues to promote the research and development of 2D, HD, 3D, 4D ICE, and related intelligent technologies.
The company’s official website shows that its R&D and product direction focuses on cardiac interventional ultrasound technology and is committed to providing new imaging solutions for clinical cardiac intervention.
About T-Capital
T-Capital is a boutique investment bank focusing on the healthcare field, providing capital transaction and strategic consulting services for healthcare companies.
Main services include:
- Equity financing;
- Domestic and foreign M&A;
- Corporate divestiture and spin-off;
- Licensing and BD transactions;
- Joint ventures and co-development;
- NewCo;
- Cross-border transactions;
- Strategic financing and capital advisory.
T-Capital has long served enterprises in the healthcare fields such as innovative drugs, medical devices, medical diagnostics, life sciences, bio-manufacturing, high-value consumables, healthcare services, and emerging technologies.
In this project, T-Capital served as the main financial advisor for the relevant financing rounds of Bingjing Intelligent, assisting the company in completing the financing.
Project Core Information
| Project | Information |
|---|---|
| Company | Bingjing Intelligent |
| Industry | Medical Devices |
| Sub-field | Interventional Ultrasound / Intracardiac Echocardiography (ICE) |
| Founded | 2021 |
| Core Application | Interventional therapy for structural heart disease, electrophysiology, etc. |
| Core Product Direction | 2D ICE, HD ICE, 3D ICE, 4D ICE |
| Financing Status | Completed two consecutive rounds of financing, with a total amount of nearly 100 million yuan |
| Investors | Bank of China International, Jiangxia Science and Technology Investment, Shengke Zhizao, etc. |
| Financial Advisor | T-Capital |
| Use of Funds | Construction of production bases, operations, and supplementary working capital |
Further Reading
T-Capital Transactions
If you are looking for opportunities in medical device financing, strategic investment, M&A, or industrial cooperation, you can learn more about T-Capital’s healthcare capital transaction services.
Related Services:
/services/private-financing//services/ma-advisory//services/strategic-partnership//services/cross-border/
Related Fields:
- Medical device financing
- Medical imaging
- Medical AI
- High-value consumables
- Healthcare industry M&A
- Medical device strategic cooperation
Disclaimer
This article is compiled based on publicly disclosed information and project-related materials, and is only for introducing the project and industry information. It does not constitute any investment advice, securities recommendation, or guarantee of the future operating performance of the relevant companies.
Some company information, financing information, and product progress may change with subsequent announcements and the company’s business development. The latest publicly disclosed information of the relevant companies and investment institutions shall prevail.